Combination therapy for resistant Sjögren's in children
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a combination of two medicines, rituximab then belimumab, for children and teens with Sjögren's syndrome that hasn't improved with other treatments. The goal is to see if this two-step approach can better control symptoms like joint pain, skin rashes, and blood problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 18 years old.
- You must have been diagnosed with Sjögren's syndrome (a condition that causes dry eyes and mouth, and can affect other parts of the body).
- You must have tried at least two other medicines or prednisone combined with another immune medicine for more than 3 months, and still have symptoms like joint pain, skin rashes, low blood counts, or organ involvement.
- You must agree to take both rituximab and belimumab (two biologic drugs that work on the immune system).
- You cannot have taken rituximab in the last 6 months, or ever taken belimumab or similar drugs before.
- You cannot have active infections (such as hepatitis B or C, HIV, tuberculosis) or a recent serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study tests a new combination of two medicines (rituximab and a low dose of mycophenolate mofetil) to help children with active lupus nephritis (kidney inflammation from lupus). The goal is to see if combining these drugs works better and is safe for children.
This trial tests whether a drug called rituximab can help children with their first episode of nephrotic syndrome stay in remission longer. It is for children who have already responded to steroid treatment.
This trial tests a new treatment (YTS109) for children with certain autoimmune diseases that have not responded to standard therapies. The treatment targets B cells, which are part of the immune system, to help calm down the immune attack.
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.